MCRB
Seres Therapeutics Inc
3.80$
-5.7%
vs. previous close
Closing price · As of: Sep 23, 2026
Statements
Balance Sheet
All figures as a percentage of total assets in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 97.4% | 95.7% | 72.8% | 81.8% | 76.9% | 75.6% | 78.4% | 85.6% | 55.8% | 48.9% | 27.7% | 35.7% | |
| 97.3% | 34.1% | 20.0% | 19.0% | 71.2% | 49.2% | 33.8% | 50.7% | 46.7% | 35.7% | 22.0% | 33.1% | |
| 97.3% | 94.6% | 70.9% | 79.1% | 71.2% | 71.6% | 74.0% | 81.9% | 52.0% | 35.7% | 22.0% | 33.1% | |
| – | – | – | – | – | 1.3% | 2.7% | 0.0% | – | 2.4% | 3.4% | 0.3% | |
| – | 0.0% | 0.0% | 0.0% | – | -22.4% | 0.0% | – | 0.0% | 8.3% | – | – | |
| 1.1% | 3.6% | 13.2% | 17.4% | 21.8% | 14.7% | 4.1% | 10.2% | 6.6% | – | – | – | |
| – | 0.0% | 0.0% | 0.0% | – | – | – | – | – | – | – | – | |
| – | 0.0% | 0.0% | 0.0% | – | – | – | – | – | – | – | – | |
| 122.8% | 5.3% | 51.4% | 68.0% | 139.9% | 136.5% | 49.0% | 62.9% | 96.9% | 112.5% | 90.1% | 68.0% | |
| 4.3% | 5.0% | 11.2% | 16.7% | 34.9% | 34.7% | 13.5% | 23.2% | 24.5% | 27.5% | 29.5% | 14.0% | |
| 1.0% | – | 2.7% | 4.9% | 10.0% | 3.4% | 1.6% | 1.9% | 1.2% | 1.6% | 6.2% | 7.5% | |
| 1.8% | 2.5% | 2.8% | 3.7% | 5.3% | 3.7% | 1.2% | 3.9% | 5.0% | 1.0% | 2.9% | 1.2% | |
| 1.1% | 0.0% | 0.0% | 0.0% | – | 18.6% | 7.2% | 6.9% | 14.5% | 28.3% | – | – | |
| -22.8% | 94.7% | 48.6% | 32.0% | -39.9% | -36.5% | 51.0% | 37.1% | 3.1% | -12.5% | 9.9% | 32.0% | |
| -23.7% | -38.1% | -63.9% | -139.1% | -323.2% | -347.1% | -160.0% | -173.1% | -247.9% | -272.8% | -699.6% | -703.7% | |
| 1.7% | 0.5% | 0.7% | 1.1% | 1.7% | 2.1% | 1.2% | 1.3% | 1.5% | 1.8% | 5.6% | 6.4% |
Data as of: September 23, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.